Related Experiment Videos
Novel approaches to the treatment of primary amyloidosis
O Sezer1, K Niemöller, C Jakob
1Department of Hematology and Oncology, Universitätsklinikum Charité, Humboldt Universität, Berlin, Germany. sezer@charite.de
Abstract:
Primary (AL, amyloid light-chain) amyloidosis is a plasma cell disorder in which deposits of amyloid light-chain protein cause progressive organ failure. It is important to recognise that amyloidosis is a dynamic process and chemotherapy-induced reduction of the activity of the plasma cell clone reduces the supply of the amyloid precursor protein and can result in a major regression of the deposits. The most common target organ is the kidney and renal amyloidosis manifests as proteinuria or nephrotic syndrome. Proteinuria is seen in three quarters of patients. Amyloid related nephrotic syndrome and renal failure are potentially reversible. Fatigue, congestive heart failure, hepatomegaly, peripheral neuropathy, orthostatic hypotension, carpal tunnel syndrome and macroglossia are other common features. The median survival is one to two years. Conventional-dose melphalan as standard treatment can prolong the median duration of survival by about ten months, but the clinical response rates with improvement of impaired organ function are low. Up-front high-dose chemotherapy with autologous peripheral blood stem cell transplantation is much more effective and can result in a major improvement in the clinical condition of patients. However, the toxicity related to this treatment can be relevant due to impaired organ function. Conventional-dose chemotherapy consisting of vincristine, doxorubicin and dexamethasone or high-dose dexamethasone or interferon-alpha are other possible approaches to treatment. The improvement of patient condition with an effective conventional-dose chemotherapy may increase the tolerability of high-dose chemotherapy and reduce transplantation related problems.
Insights
Primary amyloidosis (AL) involves amyloid light-chain protein deposits causing organ failure. Effective chemotherapy can reduce deposits and improve organ function, offering better survival outcomes for patients.
Area of Science:
- Hematology
- Nephrology
- Oncology
Background:
- Primary amyloidosis (AL) is a plasma cell disorder characterized by amyloid light-chain protein deposition, leading to progressive organ damage.
- Kidney involvement (renal amyloidosis) is common, presenting as proteinuria or nephrotic syndrome, and can be reversible.
- Existing treatments like conventional-dose melphalan offer limited response rates and survival benefits.
Purpose of the Study:
- To review the dynamic nature of amyloidosis and the impact of chemotherapy on disease regression.
- To evaluate the effectiveness of different treatment modalities, including high-dose chemotherapy with stem cell transplantation.
- To discuss potential strategies for improving treatment tolerability and outcomes.
Main Methods:
- Literature review of primary amyloidosis (AL) pathogenesis, clinical manifestations, and treatment outcomes.
- Analysis of the efficacy and toxicity of conventional-dose chemotherapy and high-dose chemotherapy with autologous stem cell transplantation.
- Discussion of treatment sequencing and patient management.
Main Results:
- Chemotherapy-induced reduction in plasma cell activity decreases amyloid precursor protein, leading to deposit regression and potential organ function improvement.
- High-dose chemotherapy with autologous stem cell transplantation demonstrates superior efficacy compared to conventional-dose melphalan but carries toxicity risks.
- Conventional chemotherapy regimens (e.g., VCD, high-dose dexamethasone, interferon-alpha) are alternative treatment options.
Conclusions:
- Amyloidosis is a dynamic process responsive to chemotherapy, with potential for significant organ function recovery.
- High-dose chemotherapy with stem cell transplantation offers substantial clinical improvement but requires careful patient selection due to organ function impairment.
- Optimizing conventional chemotherapy may enhance tolerability and reduce complications associated with high-dose regimens and transplantation.